👤 Hualing Li

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
3991
Articles
2551
Name variants
Also published as: Xiaofeng Li, Jingwen Li, Jiajia Li, Zhaolun Li, Litao Li, Ruyi Li, Xiaocun Li, Jianyu Li, Wanxin Li, Jinsong Li, Xinzhi Li, Guanqiao Li, Ying-Lan Li, Zequn Li, Yulin Li, Shaojian Li, Guang-Xi Li, Yubo Li, Bugao Li, Mohan Li, Yan-Xue Li, Qingchao Li, Xikun Li, Hong-Tao Li, Enhong Li, Guobin Li, Xiangnan Li, Yong-Jun Li, Ziming Li, Hang Li, Rongqing Li, Xihao Li, Jing-Ming Li, Chang-Da Li, Meng-Yue Li, Yuanchang Li, DaZhuang Li, Xiao-Lin Li, Yicun Li, Zhao-Yang Li, Jiajie Li, Shunqin Li, Xinjia Li, K-L Li, Yaqiong Li, Bin Li, Yuan-hao Li, Jianhai Li, Peiwu Li, Youran Li, Yongmei Li, Changyu Li, Ran Li, X Y Li, Peilin Li, Chunshan Li, Yixiang Li, Ming Zhou Li, Ye Li, Z Li, Guanglve Li, Zili Li, Xinmei Li, Yihao Li, Liling Li, Qing Run Li, Wulan Li, Meng-Yang Li, Ziyun Li, Haoxian Li, Xiaozhao Li, Jun-Ying Li, Da-Lei Li, Xinhai Li, Yongjiang Li, Wanru Li, Jinming Li, Huihui Li, Wenhao Li, Qiankun Li, Kailong Li, Shengxu Li, Shisheng Li, Sai Li, Guangwen Li, Hua Li, Xiuli Li, Dongmei Li, Yulong Li, Ru-Hao Li, Zhi-Peng Li, Lanzhou Li, Tingsong Li, Binjun Li, Chen Li, Jiayang Li, Yawei Li, Zunjiang Li, Chao Bo Li, Minglong Li, Donghua Li, Wenzhe Li, Siming Li, Fengli Li, Song Li, Zihan Li, Hsin-Hua Li, Jin-Long Li, Hongxin Li, Dongfeng Li, You Li, Zhen-Yuan Li, Xueyang Li, Xuelin Li, Fa-Hui Li, Caiyu Li, Guangpu Li, Teng Li, Wen-Jie Li, Hegen Li, Ang Li, Zhizong Li, Lu-Yun Li, Peng Li, Shiyu Li, Bao Li, Yin Li, Cai-Hong Li, Fang Li, Jiuke Li, Miyang Li, Mingxu Li, Chen-Xi Li, Panlong Li, Changwei Li, Dejun Li, Biyu Li, Yufeng Li, Miaoxin Li, San-Feng Li, Yaoqi Li, Hu Li, Bei Li, Sha Li, W H Li, Jiaming Li, Jiyuan Li, Ya-Qiang Li, Rongkai Li, Yani Li, Xiushen Li, Jinlin Li, Xiaoqing Li, Linke Li, C Y Li, Shuaicheng Li, Thomas Li, Siting Li, Xuebiao Li, Yingyi Li, Yongnan Li, Maolin Li, Jiyang Li, Jinchen Li, Jin-Ping Li, Zhongxuan Li, Xuewen Li, R Li, Xianlong Li, Linting Li, Aixin Li, Zhong-Xin Li, Xuening Li, Enhao Li, Guang Li, Xiaoming Li, Shengliang Li, Yongli Li, Z-H Li, Baohong Li, Hujie Li, Yue-Ming Li, Shuyuan Li, Zhaohan Li, L Li, Yuanmei Li, Alexander Li, Yanwu Li, Wen-juan Li, Sibing Li, Qinghe Li, Xining Li, Pilong Li, Yun-Peng Li, Zonghua Li, C X Li, Jingya Li, Huanan Li, Liqin Li, Youjun Li, Zheng-Dao Li, Miao X Li, Zhenshu Li, KeZhong Li, Heng-Zhen Li, Linying Li, Chu-Qiao Li, Fa-Hong Li, Changzheng Li, Yuhui Li, Wen-Ying Li, Wei Li, Yaokun Li, Shuanglong Li, Zhi-Gang Li, Yufan Li, Liangqian Li, Guanghui Li, Xiongfeng Li, Fei-feng Li, Letai Li, Kangli Li, Ming Li, Runwen Li, Wenbo Li, Side Li, Yarong Li, S E Li, Timmy Li, Weidong Li, Xin-Tao Li, Ruotong Li, Xiuzhen Li, Shuguang Li, Chuan-Hai Li, Lingxi Li, Qiuya Li, Jiezhen Li, Haitao Li, Tingting Li, Guanghua Li, Yufen Li, Zhongyu Li, Qin Li, Deyu Li, Zhen-Yu Li, Hansen Li, Annie Li, Wenge Li, Jinzhi Li, Xueren Li, Chun-Mei Li, Yijing Li, Kaifeng Li, Wen-Xing Li, Meng-Yao Li, Chung-I Li, Zhi-Bin Li, Qintong Li, Xiao Li, Junping Li, PeiQi Li, Xiaobing Li, Naishi Li, Liangdong Li, Xin-Ping Li, Yan Li, Han-Ni Li, Pan Li, Shengchao A Li, Jiaying Li, Jun-Jie Li, Ruonan Li, Cui-lan Li, Shuhao Li, Huiqiong Li, Ruitong Li, Guigang Li, Lucia M Li, Chunzhu Li, Suyan Li, Chengquan Li, Zexu Li, Gen-Lin Li, Dianjie Li, Zhilei Li, Junhui Li, Tiantian Li, Xue Cheng Li, Ya-Jun Li, Wenyong Li, Ding-Biao Li, Tianjun Li, Desen Li, Yansong Li, Xiying Li, Zihao Li, Weiyong Li, Xinyang Li, Fadi Li, Huawei Li, Yu-quan Li, Cui Li, Xiaoyong Li, Y L Li, Xueyi Li, Jingxiang Li, Wenxue Li, Jihua Li, Jingping Li, Zhiquan Li, Zeyu Li, Yingpu Li, Jianglin Li, Yan-Hua Li, Jing-Yao Li, Zongdi Li, Ming V Li, Shawn Shun-Cheng Li, Aowen Li, Xiao-Min Li, Wan Jie Li, L K Li, Ya-Ting Li, Aimin Li, Dongbiao Li, Tiehua Li, Keguo Li, Yuanfei Li, Longhui Li, Jing-Yi Li, Zhonghua Li, Guohong Li, Chunyi Li, Botao Li, Peiyun Li, Xiuqi Li, L-Y Li, Qinglan Li, Zhenhua Li, Zhengda Li, Haotong Li, Yue-Ting Li, Luhan Li, Da Li, Yuancong Li, Yuxiu Li, Tian Li, YiPing Li, Beibei Li, Demin Li, Haipeng Li, Chuan Li, Changhong Li, Ze-An Li, Jianmin Li, Yu Li, Yvonne Li, Minhui Li, Yiwei Li, Xiangzhe Li, Zhichao Li, Jiayuan Li, Minglun Li, Siguang Li, Yige Li, Chengqian Li, Weiye Li, Xue-Min Li, Kenneth Kai Wang Li, Dong-fei Li, Xiangchun Li, Chunlan Li, Chiyang Li, Hulun Li, Juan-Juan Li, Hua-Zhong Li, Hailong Li, Kun-Peng Li, Jiaomei Li, Haijun Li, Jing Li, Si Li, Xiangyun Li, Ji-Feng Li, Yingshuo Li, Wanqian Li, Baixing Li, Dengke Li, Zijing Li, Yuchuan Li, Wentao Li, Qingling Li, Rui-Han Li, Xuhong Li, Dong Li, Hongyun Li, Zhonggen Li, Xiong Li, Penghui Li, Xiaoxia Li, Dezhi Li, Huiting Li, Xiaolong Li, Linqing Li, Jiawei Li, Sheng-Jie Li, Defa Li, Ying-Qing Li, X L Li, Yuyan Li, Kawah Li, Xin-Jian Li, Guangxi Li, Yanhui Li, Shupeng Li, Zhenfei Li, Sha-Sha Li, Ziyu Li, Mengxuan Li, Panyuan Li, Gang Li, Zhuo Li, Hong-Wen Li, Han-Wei Li, Xiaojuan Li, Weina Li, Xiao-Hui Li, Huaiyuan Li, Dongnan Li, Rui-Fang Li, Jianzhong Li, Huaping Li, Ji-Liang Li, C H Li, Bohua Li, Bing Li, Pei-Ying Li, Huihuang Li, Shaobin Li, Yunmin Li, Yanying Li, Ronald Li, Gui Lin Li, Chenrui Li, Shi-Hong Li, Shilun Li, Xinyu Li, John Zhong Li, Lujiao Li, Song-Chao Li, Chenghong Li, Dengfeng Li, Baohua Li, Nianfu Li, N Li, Xiaotong Li, Chensheng Li, Ming-Qing Li, Yongxue Li, Bao-Shan Li, Zhimei Li, Jiao Li, Jun-Cheng Li, Yimeng Li, Jingming Li, Jinxia Li, De-Tao Li, Chunting Li, Shu Li, Julia Li, Chien-Feng Li, Huilan Li, Mei-Zhen Li, Xin-Ya Li, Zhengjie Li, Chunsheng Li, Yan-Yan Li, Liwei Li, Huijun Li, Chengyun Li, Chengjian Li, Ying-na Li, Guihua Li, Zhiyuan Li, Supeng Li, Lijun Li, Hening Li, Yiju Li, Yuanhe Li, Guangxiao Li, Fengxia Li, Xueqin Li, Peixin Li, Feng-Feng Li, Zu-Ling Li, Jialing Li, Xin Li, Yunjiu Li, Dayong Li, Zonghong Li, Ningyan Li, Lingjiang Li, Yuhan Li, Zhenghui Li, Fuyuan Li, Ailing Li, H-F Li, Chunxia Li, Chaochen Li, Zhen-Li Li, Tengyan Li, Xianlu Li, Jiaqi Li, Jiabei Li, Zhengying Li, Yali Li, Zhaoshui Li, Wenjing Li, Yu-Hui Li, Jingshu Li, Chuang Li, Jiajun Li, Can Li, Zhe Li, Han-Bo Li, Stephen Li, Shuangding Li, Zengyang Li, Kaiyuan Li, Mangmang Li, Chunyan Li, Runzhen Li, Xiaopeng Li, Xi-Hai Li, MengGe Li, Xuezhong Li, Anan Li, Luying Li, Jiajv Li, Pei-Lin Li, Xiaoquan Li, Ning Li, Ruobing Li, Yanxi Li, Wan-Xin Li, Xia Li, Yongjing Li, Meitao Li, Ziqiang Li, Huayao Li, Wen-Xi Li, Shenghao Li, Jiqing Li, Boxuan Li, Huixue Li, Hehua Li, Yucheng Li, Qingyuan Li, Yongqi Li, Fengqi Li, Zhigang Li, Yuqing Li, Guiyang Li, Guo-Qiang Li, Dujuan Li, Yanbo Li, Yuying Li, Shaofei Li, Sanqiang Li, Shaoguang Li, Min-Rui Li, Hongyu Li, Guangping Li, Shuqiang Li, Dan C Li, Huashun Li, Jinxin Li, Ganggang Li, Xinrong Li, Haoqi Li, Yayu Li, Handong Li, Huaixing Li, Yan-Nan Li, Xianglong Li, Minyue Li, Hong-Mei Li, Jing-Jing Li, Songhan Li, Mengxia Li, Conglin Li, Jutang Li, Qingli Li, Yongxiang Li, Miao Li, Songlin Li, Qilong Li, Dijie Li, Chenyu Li, Yizhe Li, Ke Li, Yan Bing Li, Jiani Li, Lianjian Li, Yiliang Li, Zhen-Hua Li, Chuan-Yun Li, Xinpeng Li, Hongxing Li, Wanyi Li, Gaoyuan Li, Youming Li, Mi Li, Dong-Yun Li, Qingrun Li, Guo Li, Jingxia Li, Xiu-Ling Li, Fuhai Li, Ruijia Li, Shuangfei Li, Yumiao Li, Fengfeng Li, Jiexi Li, Qinggang Li, Huixia Li, Kecheng Li, Junxu Li, Xiangjun Li, Xingye Li, Junya Li, Jiang Li, Huiying Li, Shengxian Li, Qingyang Li, Yuxi Li, Xiao-Dong Li, Chenxuan Li, Xinghuan Li, Zhaoping Li, Xingyu Li, Zhenlu Li, Xiaolei Li, Wenying Li, Huilong Li, Xiao-Gang Li, Honghui Li, Zhenhui Li, Cheung Li, Zhenming Li, Xuelian Li, Shu-Fen Li, Chunjun Li, Changyan Li, Yinghua Li, Mulin Jun Li, Shangjia Li, Yanjie Li, Jingjing Li, Suhong Li, Xinping Li, Chaoying Li, Siyu Li, Qiu Li, Juanjuan Li, Xiangyan Li, Guangzhen Li, Kunlun Li, Shiyun Li, Xiaoyu Li, Yaobo Li, Shiquan Li, Mei Li, Xuewang Li, Xiangdong Li, Jifang Li, Zhenjia Li, Manjiang Li, Wan Li, Zhizhong Li, Ding Yang Li, Xiaoya Li, Xiao-Li Li, Shan Li, Shitao Li, Lijia Li, Zehan Li, Chunqiong Li, Huiliang Li, Junjun Li, Chenlong Li, Shujin Li, Hui-Long Li, Zhao-Cong Li, Zhi-Wei Li, Weining Li, Wenxi Li, Wu-Jun Li, Chang-hai Li, Bin-Kui Li, Yumao Li, Yuqiu Li, Honglian Li, Xue-Yan Li, Ya-Zhou Li, Yuan-Yuan Li, Hongyi Li, Xiang-Jun Li, Y X Li, Chia Li, Yunyun Li, Zhen-Jia Li, Fu-Rong Li, Honghua Li, Lanjuan Li, Qiuxuan Li, Xiancheng Li, Man-Zhi Li, Yanmei Li, De-Jun Li, Zhihua Li, Junxian Li, Keqing Li, Shuwen Li, Danxi Li, Minqi Li, Saijuan Li, Lingjun Li, Mimi Li, Si-Xing Li, Deheng Li, Yingjie Li, Yaodong Li, Shigang Li, Yuan-Hai Li, Lujie Li, Minghao Li, Gao-Fei Li, Minle Li, Meifen Li, Yifeng Li, Le-Le Li, Huanqing Li, Ziwen Li, Yuhang Li, Yongqiu Li, Pu-Yu Li, Jianhua Li, Chanjuan Li, Nan-Nan Li, Hongming Li, Lan-Lan Li, Yanchuan Li, Lingyi Li, Shuang Li, Wanting Li, Bai-Qiang Li, Gong-Hua Li, Zhengyu Li, Chunmiao Li, Jiong-Ming Li, Yongqiang Li, Linsheng Li, Weiguang Li, Mingyao Li, Guoqing Li, Ze Li, Xiaomeng Li, R H L Li, Yuanze Li, Yunqi Li, Yuandong Li, Guisen Li, Jinglin Li, Dongyang Li, Mingfang Li, Honglong Li, Hanmei Li, Chenmeng Li, Changcheng Li, Shiyang Li, Shiyue Li, Hanbo Li, Jianing Li, Dingshan Li, Yinggao Li, Linlin Li, Xinsheng Li, Jin-Wei Li, Jin-Jiang Li, Cheng-Tian Li, Zhi-Xing Li, Chang Li, Yaxi Li, Ming-Han Li, Wei-Ming Li, Wenchao Li, Guangyan Li, Xuesong Li, Zhaosha Li, Jiwei Li, Chun-Quan Li, Yongzhen Li, Weifeng Li, Tao Li, Sichen Li, Wenhui Li, Xiankai Li, Qingsheng Li, Yaxuan Li, Liangji Li, Lixiang Li, Tian-wang Li, Yuchan Li, Jiaxi Li, Yalin Li, Jin-Liang Li, Pei-Zhi Li, You Ran Li, Xiaoqiong Li, Guanyu Li, Yixiao Li, Jinlan Li, Huizi Li, Jianping Li, Kathy H Li, Yun-Lin Li, Yadong Li, Sujing Li, Yuhua Li, Xuri Li, Wenzhuo Li, Y Li, Deqiang Li, Caixia Li, Mingyue Li, Zipeng Li, Hongli Li, Yun Li, Mengqiu Li, Ling-Ling Li, Yaqin Li, Yanfeng Li, Yu-He Li, Shasha Li, Xi Li, S-C Li, Siyi Li, Minmin Li, Manna Li, Chengwen Li, Dawei Li, Shu-Feng Li, Haojing Li, Xun Li, Ming-Jiang Li, Zhiyu Li, Sitao Li, Ziyang Li, Qian Li, Yaochen Li, Tinghua Li, Zhenfen Li, Wenyang Li, Bohao Li, Shuo Li, Wenming Li, Mingxuan Li, Si-Ying Li, Xinyi Li, Jenny J Li, Xue-zhi Li, Anqi Li, Bingsong Li, Shuai Li, Xiaoju Li, Ting Li, Zhenyu Li, Xiaonan Li, Duan Li, Xiang-Yu Li, Lei Li, Hongde Li, Fengqing Li, Na Li, Yanchang Li, Xunjia Li, Huibo Li, Ruixia Li, Nanzhen Li, Chuanfang Li, Bingjie Li, Hongxue Li, Pengsong Li, Ruotian Li, Xiaojing Li, Xinlin Li, En-Min Li, Zong-Xue Li, Chunya Li, Yan Ning Li, Honglin Li, Yu-Ying Li, Jinhua Li, Min-jun Li, Qian-Qian Li, Yuanheng Li, Chunxiao Li, Wenli Li, Shijun Li, Mengze Li, Kuan Li, Baoguang Li, Kaiwei Li, Jie-Shou Li, Zimeng Li, Mengmeng Li, W-B Li, Huangyuan Li, Lili Li, Binkui Li, Yu-Sheng Li, Junxin Li, Wei-Jun Li, Guoyan Li, Junjie Li, Fei-Lin Li, Nuomin Li, Shanglai Li, Shulin Li, Yanyan Li, Yue Li, Taibo Li, Junqin Li, Jun-Ru Li, JunBo Li, Zhongcai Li, Xueying Li, Zhaobing Li, Xiaoqi Li, Xiucui Li, Haihua Li, Linxin Li, Yu-Lin Li, Jen-Ming Li, Shujing Li, Tsai-Kun Li, Chen-Chen Li, Hongquan Li, Chuan F Li, Mengyun Li, Mingna Li, Yanxiang Li, Lanlan Li, Moyi Li, Xiyun Li, Yi-Wen Li, Huifeng Li, Rulin Li, Shihong Li, Ya-Pei Li, Lijuan Li, Shengbin Li, Yuanhong Li, Zhongjie Li, Zhenbei Li, Jingyu Li, Xuewei Li, Long Li, Shuangshuang Li, Min-Dian Li, Wenjia Li, Xiatian Li, Hongwei Li, Ding-Jian Li, Danni Li, Yangxue Li, Xiao-Qiang Li, Chengnan Li, Chuanyin Li, Min Li, Zhenzhou Li, Yiqiang Li, Pengyang Li, Kun-Xin Li, Xiawei Li, Binglan Li, Zesong Li, Xiangpan Li, Yutong Li, Mingfei Li, Shuwei Li, Yingnan Li, Ge Li, Mingdan Li, Xihe Li, Xinzhong Li, Jianfeng Li, Chenyao Li, Jun-Yan Li, Dexiong Li, Rongsong Li, Yinxiong Li, Boru Li, Ruixue Li, Zemin Li, Jixi Li, Chris Li, Jicheng Li, Hong-Yu Li, Chuanning Li, Weijian Li, Changhui Li, Jiafei Li, Yingying Li, Gaizhi Li, Chien-Hsiu Li, Xiangcheng Li, Siqi Li, Dechao Li, Chunxing Li, Wenxia Li, Guoxiang Li, Ziru Li, Qiao-Xin Li, Shu-Fang Li, Huang Li, Qiusheng Li, Man Li, Juxue Li, Weiqin Li, Xinming Li, Huayin Li, Xiao-yu Li, Jianyi Li, Yongjun Li, Mengyang Li, Guo-Jian Li, Guowei Li, Chenglong Li, Xingya Li, Nan Li, Gongda Li, Yajun Li, Wei-Ping Li, Yipeng Li, Mingxing Li, Nanjun Li, Xin-Yu Li, Chunyu Li, P H Li, Jinwei Li, Xuhua Li, Yu-Xiang Li, Ranran Li, Suping Li, Long Shan Li, Yanze Li, Jason Li, Xiao-Feng Li, Fengjuan Li, W Li, Monica M Li, Xianlun Li, Hainan Li, Qi Li, Yutian Li, Xiaoli Li, Xiliang Li, Shuangmei Li, Fei Li, Ying-Bo Li, Xionghui Li, Duanbin Li, Maogui Li, Dan Li, Sumei Li, Hongmei Li, Peilong Li, Kang Li, Yinghao Li, Xu-Wei Li, Mengsen Li, Lirong Li, Quanpeng Li, Wenhong Li, Audrey Li, Yijian Li, Yajiao Li, Guang Y Li, Xianyong Li, Qilan Li, Shilan Li, Qiuhong Li, Zongyun Li, Xiao-Yun Li, Guang-Li Li, Cheng-Lin Li, Bang-Yan Li, Enxiao Li, Jianrui Li, Yousheng Li, Guohua Li, Wen-Ting Li, Kezhen Li, Xingxing Li, Guoping Li, Ellen Li, A Li, Simin Li, Yijie Li, Xue-Nan Li, Weiguo Li, Xiaoying Li, Suwei Li, Shengsheng Li, Shuyu D Li, Jiandong Li, Ruiwen Li, Fangyong Li, Hong Li, Binru Li, Yuqi Li, Zihua Li, Yuchao Li, Hanlu Li, Xue-Peng Li, Jianang Li, Qing Li, Jiaping Li, Sheng-Tien Li, Yazhou Li, Shihao Li, Jun-Ling Li, Caesar Z Li, Feng Li, Weiyang Li, Lang Li, Peihong Li, Jin-Mei Li, Lisha Li, Feifei Li, Kejuan Li, Qinghong Li, Qiqiong Li, Cuicui Li, Kaibo Li, Xinxiu Li, Chongyi Li, Yi-Ying Li, Hanbing Li, Shaodan Li, Meng-Hua Li, Yongzheng Li, J T Li, Da-Hong Li, Xiao-mei Li, Jiejie Li, Ruihuan Li, Xiangwei Li, Baiqiang Li, Ziliang Li, Yaoyao Li, Yueguo Li, Mo Li, Zheng Li, Ming-Hao Li, Donghe Li, Congfa Li, Wenrui Li, Hongsen Li, Yong Li, Xiuling Li, Menghua Li, Jingqi Li, Ka Li, Kaixin Li, Fuping Li, Zhiyong Li, Jianbo Li, Xing-Wang Li, Chong Li, Xiao-Kang Li, Fugen Li, Hanqi Li, Yangyang Li, Yuwei Li, Dongfang Li, Xiaochen Li, Zhuorong Li, Zizhuo Li, X-H Li, Lan-Juan Li, Dong Sheng Li, Xianrui Li, Zhigao Li, Chenlin Li, Zihui Li, Xiaoxiao Li, Guoli Li, Le-Ying Li, Pengcui Li, Huanqiu Li, Xiaoman Li, Bing-Heng Li, Zhan Li, Weisong Li, Xinglong Li, Xiaohong Li, Xiaozhen Li, Yuan Hao Li, Jianchun Li, Wenxiang Li, Zhaoliang Li, Guo-Ping Li, Zhiyang Li, Cunxi Li, Zhifei Li, Jinhui Li, Ying Li, Yanshu Li, Jianlin Li, Yuanyou Li, Chongyang Li, Yumin Li, Wanyan Li, Longyu Li, Jinku Li, Guiying Li, X B Li, Changgui Li, Zhisheng Li, Cuiling Li, Xuekun Li, Yuguang Li, Wenke Li, Jianguo Li, Jiayi Li, En Li, Ximei Li, Shaoyong Li, Peihua Li, Kai-Wen Li, Suwen Li, Chang-Ping Li, Guangda Li, Yixue Li, Guandu Li, Junfeng Li, Xin-Chang Li, Jieming Li, Yue-Ying Li, Kongdong Li, Chunhui Li, Tongyao Li, Peiyu Li, Lian Li, Linfeng Li, Yuzhe Li, Xinmiao Li, Chenyang Li, Jiacheng Li, Chang-Yan Li, Xiaohua Li, Qifang Li, Duanxiang Li, Xiaolin Li, Vivian Li, Meiting Li, Justin Li, Xue-Er Li, Zhuangzhuang Li, Xiaohui Li, Hongchang Li, Cang Li, Xuepeng Li, Mingjiang Li, Youwei Li, Ronggui Li, Xingwang Li, Tiange Li, Yongjia Li, Dacheng Li, Zongyu Li, Xinmin Li, Luquan Li, Guoxing Li, Jianyong Li, Shujie Li, Zongchao Li, Yanbin Li, Jia Li, Shiliang Li, Haimin Li, Qinrui Li, Sheng-Qing Li, Yiming Li, Lingjie Li, Xiao-Tong Li, Yiwen Li, Tie Li, Baoqi Li, Wei-Bo Li, Leyao Li, Xiaoyi Li, Liyan Li, Xiao-Qin Li, Xiaokun Li, Xinke Li, Ming-Wei Li, Minzhe Li, Wenfeng Li, Jiajing Li, Karen Li, Yanlin Li, X Li, Liao-Yuan Li, Meifang Li, Yanjing Li, Yongkai Li, Maosheng Li, Ju-Rong Li, Jin Li, Shibo Li, Hangwen Li, Li-Na Li, Hengguo Li, An-Qi Li, Xuehua Li, Hui Li, AnHai Li, Chenli Li, Rumei Li, Zhengrui Li, Fangqi Li, Xiaoguang Li, Xian Li, Danjie Li, Yan-Yu Li, Vivian S W Li, Qinghua Li, Lipeng Li, Qinqin Li, Leilei Li, Ranchang Li, Defu Li, Lianyong Li, Amy Li, Zhou Li, Q Li, Haoyu Li, Xiaoyao Li, M-J Li, Jiao-Jiao Li, Zhu Li, Rongling Li, Tong-Ruei Li, Bizhi Li, Cheng-Wei Li, Wenwen Li, Guangqiang Li, Jian'an Li, Ben Li, Sichong Li, Wenyi Li, Yingxia Li, Meiyan Li, Qing-Min Li, Yonghe Li, Yun-Da Li, Xinwei Li, Shunhua Li, Yu-I Li, Mingxi Li, Jian-Qiang Li, Yingrui Li, Chenfeng Li, Qionghua Li, Guo-Li Li, Xingchen Li, Ziqi Li, Shen Li, Tianjiao Li, Shufen Li, Gui-Rong Li, Yunfeng Li, Yueqi Li, Yunpeng Li, Qiong Li, Xiao-Guang Li, Jiali Li, Zhencheng Li, Qiufeng Li, Songyu Li, Xu Li, Pinghua Li, Shi-Fang Li, Shude Li, Yaxiong Li, Zhibin Li, Zhenli Li, Qing-Fang Li, Rosa J W Li, Yunxiao Li, Hsin-Yun Li, Shengwen Li, Gui-Bo Li, XiaoQiu Li, Xueer Li, Zhi Li, Zhankui Li, Zihai Li, Yue-Jia Li, Haihong Li, Peifen Li, Mingzhou Li, Taixu Li, Jiejing Li, Meng-Miao Li, Meiying Li, Chunlian Li, Meng Li, Zhijie Li, Cun Li, Huimin Li, T Li, Ruifang Li, Xiao-xu Li, Man-Xiang Li, Cong Li, Yinghui Li, Chengbin Li, Feilong Li, Yuping Li, Sin-Lun Li, Weiling Li, Mengfan Li, Jie Li, Shiyan Li, G Li, Lianbing Li, Yanchun Li, Xuze Li, Zhi-Yong Li, Yukun Li, Jialin Li, Wenjian Li, He Li, Bichun Li, Xiong Bing Li, Hanqin Li, Qingjie Li, Wen Lan Li, Guoge Li, Han Li, Wen-Wen Li, Keying Li, Yutang Li, Minze Li, Xingcheng Li, Wanshun Li, Congxin Li, Hankun Li, Hongling Li, Xiangrui Li, Caolong Li, Chaojie Li, Michelle Li, Zhifan Li, J Li, Zhi-Jian Li, Jianwei Li, Yan-Guang Li, Jiexin Li, Hongyan Li, Ji-Min Li, Zhen-Xi Li, Guangdi Li, Peipei Li, Tian-Yi Li, Xiaxia Li, Yuefeng Li, Nien Li, Zhihao Li, Peiyuan Li, Yao Li, Zheyun Li, Tiansen Li, Chi-Yuan Li, Xiangfei Li, Xue Li, Zhonglin Li, Fen Li, Jieshou Li, Lin Li, Chenjie Li, Jinfang Li, Roger Li, Yanming Li, Hong-Lan Li, Ben-Shang Li, Mengqing Li, S L Li, Ming-Kai Li, Shunqing Li, Xionghao Li, Lan Li, Menglu Li, Huiqing Li, Yanwei Li, Yantao Li, Chien-Te Li, Wenyan Li, Xiaoheng Li, Zeyuan Li, Yongle Li, Ruolin Li, Hongqin Li, Zhenhao Li, Jonathan Z Li, Haying Li, Shao-Dan Li, Yong-Liang Li, Muzi Li, Gen Li, M Li, Dong-Ling Li, Chenwen Li, Jiehan Li, Le Li, Yong-Jian Li, Hongguo Li, Chenxin Li, Yongsen Li, Qingyun Li, Pengyu Li, Si-Wei Li, Ai-Qin Li, Zichao Li, Manru Li, Yingxi Li, Caili Li, Yuqian Li, Guannan Li, Wei-Dong Li, Cien Li, Qingyu Li, Xijing Li, Jingshang Li, Xingyuan Li, Dehua Li, Wenlong Li, Ya-Feng Li, Yanjiao Li, Jia-Huan Li, Yuna Li, Xudong Li, Guoxi Li, Xingfang Li, Shugang Li, Shengli Li, Jisheng Li, Rongyao Li, Xuan Li, Yongze Li, Yongxin Li, Ru Li, Lu Li, Jiangya Li, Yiche Li, Yilang Li, Zhuo-Rong Li, Bingbing Li, Qinglin Li, Runzhi Li, Yunshen Li, Jingchun Li, Qi-Jing Li, Hexin Li, H J Li, Yanping Li, Zhenyan Li, Ji Xia Li, Yu-Ye Li, Meizi Li, Qing-Wei Li, Yuezheng Li, Qiang Li, Hsiao-Hui Li, Zhengnan Li, L I Li, Jianglong Li, Hongzheng Li, Laiqing Li, Zhongxia Li, Ningyang Li, Guangquan Li, Xiaozheng Li, Hui-Jun Li, Shun Li, Guojun Li, Xuefei Li, Senlin Li, Hung Li, Jinping Li, Huili Li, Sainan Li, Jinghui Li, Zulong Li, Chengsi Li, P Li, Hongzhe K Li, Fulun Li, Xiao-Qiu Li, Jiejia Li, Yonghao Li, Mingli Li, Yehong Li, Zhihui Li, Yi-Yang Li, Fujun Li, Pei Li, Quanshun Li, Yongping Li, Liguo Li, Ni Li, Weimin Li, Mingxia Li, Xue-Hua Li, M V Li, Luxuan Li, Qiang-Ming Li, Yakui Li, Huafu Li, Xinye Li, Gan Li, Shichao Li, Chunliang Li, Ruiyang Li, Dapei Li, Zejian Li, Chun Li, Lihong Li, Jianan Li, Wenfang Li, Haixia Li, Xiangling Li, Sung-Chou Li, Lianhong Li, Jingmei Li, Ao Li, Yitong Li, Siwen Li, Yanlong Li, Cheng Li, Kui Li, Zhao Li, Tiegang Li, Yunxu Li, Shuang-Ling Li, Zhong Li, Xiao-Long Li, Hung-Yuan Li, Xiaofei Li, Xuanfei Li, Zilin Li, Zhang Li, Jianxin Li, Mingqiang Li, H Li, Xiaojiao Li, Dongliang Li, Yinzhen Li, Chenxiao Li, Hongjia Li, Xiao-Jing Li, Li-Min Li, Yunsheng Li, Xiangqi Li, Y H Li, Jian Li, Jia-Peng Li, Baichuan Li, Daoyuan Li, Haibo Li, Wenqi Li, Zhenzhe Li, Jian-Mei Li, Xiao-Jun Li, Kaimi Li, Yan-Hong Li, Peiran Li, Shi Li, Xueling Li, Qiao Li, Yi-Yun Li, Xiao-Cheng Li, Conghui Li, Xiaoxiong Li, Wanni Li, Yike Li, Yihan Li, Chitao Li, Haiyang Li, Jiayu Li, Xiaobai Li, Junsheng Li, Pingping Li, Mingquan Li, Wen-Ya Li, Suran Li, Rongxia Li, Yunlun Li, Yingqin Li, Yuanfang Li, Guoqin Li, Qiner Li, Huiqin Li, Shanhang Li, Jiafang Li, Chunlin Li, Han-Bing Li, Zongzhe Li, Yikang Li, Jisen Li, Si-Yuan Li, Caihong Li, Hongmin Li, Yajing Li, Peng Peng Li, Kenli Li, Guanglu Li, Benyi Li, Yuquan Li, Xiushi Li, Hongzhi Li, Jian-Jun Li, Dongmin Li, Fengyi Li, Yanling Li, Chengxin Li, Juanni Li, Xiaojiaoyang Li, C Li, Jian-Shuang Li, Xinxin Li, You-Mei Li, Chenglan Li, Dazhi Li, Yubin Li, Beixu Li, Yuhong Li, Fengqiao Li, Di Li, Guiyuan Li, Yanbing Li, Suk-Yee Li, Yuanyuan Li, Jufang Li, Shengjie Li, Xiaona Li, Shanyi Li, Hongbo Li, Chih-Chi Li, Xinhui Li, Zecai Li, Qipei Li, Xiaoning Li, Jun Li, Minghua Li, Xiyue Li, Zhuoran Li, Tianchang Li, Hongru Li, Shiqi Li, Mei-Ya Li, Wuyan Li, Mingzhe Li, Yi-Ling Li, Hongjuan Li, Yingjian Li, Zhirong Li, Wang Li, Mingyang Li, Weijun Li, Boyang Li, Senmao Li, Cai Li, Mingjie Li, Ling-Jie Li, Hong-Chun Li, Jingcheng Li, Ivan Li, Yaying Li, Mengshi Li, Liqun Li, Manxia Li, Ya Li, Changxian Li, Wen-Chao Li, Dan-Ni Li, Sunan Li, Zhencong Li, Chunqing Li, Lai K Li, Jiong Li, Yanni Li, Daiyue Li, Bingong Li, Xiujuan Li, Yongsheng Li, Huifang Li, Lingling Li, Chunxue Li, Yunlong Li, Xinhua Li, Jianshuang Li, Juanling Li, Minerva X Li, Xinbin Li, Alexander H Li, Xue-jing Li, Yuling Li, Wendeng Li, Ding Li, Xianlin Li, Yetian Li, Chuangpeng Li, Mingrui Li, Linyan Li, Yanjun Li, Shengze Li, Ming-Yang Li, Jiequn Li, Zhongding Li, Hewei Li, Da-Jin Li, Jiangui Li, Zhengyang Li, Cyril Li, Xinghui Li, Yuefei Li, Xiao-kun Li, Xinyan Li, Yuanhao Li, Xiaoyun Li, Ji-Lin Li, Congcong Li, Ping'an Li, Yushan Li, Juan Li, Huan Li, Weiping Li, Changjiang Li, Chengping Li, G-P Li, He-Zhen Li, Xiaobin Li, Shaoqi Li, Yuehua Li, Yinliang Li, Wen Li, Jinfeng Li, Shiheng Li, Yu-Kun Li, Hsiao-Fen Li, Jiangan Li, Weihai Li, Zhaojin Li, Mengjiao Li, Bingxin Li, Wenjuan Li, Meng-Meng Li, Tianxiang Li, Wenyu Li, Chia-Yang Li, Liangkui Li, Tian-chang Li, Hairong Li, Yahui Li, Su Li, Wenlei Li, Xi-Xi Li, Mei-Lan Li, Wenjun Li, Haiyan Li, Jiaxin Li, Ming D Li, Chenguang Li, Ruyue Li, Xujun Li, Chi-Ming Li, Xiaolian Li, Dandan Li, Yi-Ning Li, Yunan Li, Zechuan Li, Zhijun Li, Jiazhou Li, Sherly X Li, Wanling Li, Ya-Ge Li, Yinyan Li, Rujia Li, Qijun Li, Guangli Li, Lixia Li, Zhiwei Li, Xueshan Li, Yunrui Li, Yuhuang Li, Shanshan Li, Jiangbo Li, Xiaohan Li, Wan-Shan Li, Zhongwen Li, Huijie Li, W W Li, Yalan Li, Yiyang Li, Jing-gao Li, Xuejun Li, Fengxiang Li, Nana Li, Shunwang Li, Chao Li, Yaqing Li, Bingsheng Li, Yaqiao Li, Jingui Li, Huamao Li, Xiankun Li, Jingke Li, Xiaowei Li, Tianyao Li, Junming Li, Jianfang Li, Shubo Li, Qi-Fu Li, Zi-Zhan Li, Hai-Yun Li, Haoran Li, Zhongxian Li, Xiaoliang Li, Xinyuan Li, Maoquan Li, H-J Li, Chumei Li, Zhixiong Li, Shijie Li, Lingyan Li, Zhanquan Li, Wenguo Li, Fangyuan Li, Xuhang Li, Xiaochun Li, Chen-Lu Li, Xinjian Li, Jialun Li, Rui Li, Zilu Li, Xuemin Li, Zezhi Li, Sheng-Fu Li, Xue-Fei Li, Yudong Li, Shanpeng Li, Hongjiang Li, Wei-Na Li, Dong-Run Li, Yunxi Li, Jingyun Li, Xuyi Li, Binghua Li, Hanjun Li, Yunchu Li, Jin-Qiu Li, Zhengyao Li, Qihua Li, Jiaxuan Li, Jinghao Li, Y-Y Li, Xiaofang Li, Tuoping Li, Pengyun Li, Guangjin Li, Xutong Li, Lin-Feng Li, Ranwei Li, Kai Li, Ziqing Li, Wei-Li Li, Keanning Li, Yongjin Li, Shuangxiu Li, Chenhao Li, Ling Li, Weizu Li, Deming Li, Peiqin Li, Xiaodong Li, Nanxing Li, Qihang Li, Jianrong Li, Baoguo Li, Zhehui Li, Chenghao Li, Jiuyi Li, Chun-Xu Li, Luyao Li, Desheng Li, Weike Li, Long-Yan Li, Zhixuan Li, Chuanbao Li, Fuyu Li, Chuzhong Li, M D Li, Lingzhi Li, Yuan-Tao Li, Kening Li, Guilan Li, Wanshi Li, Ling-Zhi Li, Hengtong Li, Yifan Li, Ya-Li Li, Xiao-Sa Li, Songyun Li, Xiaoran Li, Kunlin Li, Bolun Li, Linchuan Li, Jiachen Li, Haibin Li, Shu-Qi Li, Zehua Li, Huangbao Li, Guo-Chun Li, Xinli Li, Mengyuan Li, S Li, Wenqing Li, Wenhua Li, Caiyun Li, Congye Li, Xinrui Li, Dehai Li, Wensheng Li, Jiannan Li, Qingshang Li, Guanbin Li, Hanbin Li, Zhiyi Li, Xing Li, Wanwan Li, Jia Li Li, Zhaoyong Li, SuYun Li, Shiyi Li, Wan-Hong Li, Mingke Li, Suchun Li, Huanhuan Li, Xiaoyuan Li, Yanan Li, Zongfang Li, Jiayan Li, Yang Li, YueQiang Li, Xiangping Li, H-H Li, Jinman Li, BoWen Li, Duoyun Li, Dongdong Li, Yimei Li, Hao Li, Liliang Li, Mengxi Li, Keyuan Li, Zhi-qiang Li, Shaojing Li, S S Li, Yi-Ting Li, Jiangxia Li, Yujie Li, Tong Li, Lihua Li, Yilong Li, Xue-Lian Li, Zhiping Li, Yan-Li Li, Haiming Li, Yansen Li, Gaijie Li, Yanli Li, Yuemei Li, Jingfeng Li, Zhi-Yuan Li, Hai Li, Kaibin Li, Yuan-Jing Li, Xuefeng Li, Xiaohu Li, Wenjie Li, Ruikai Li, Mengjuan Li, Xiao-Hong Li, Yinglin Li, Yaofu Li, Ren-Ke Li, Qiyong Li, Ruixi Li, Yi Li, Baosheng Li, Zhonglian Li, Yujun Li, Mian Li, Dalin Li, Lixi Li, Jin-Xiu Li, Kun Li, Qizhai Li, Jiwen Li, Pengju Li, Peifeng Li, Zhouhua Li, Ai-Jun Li, Qingqin S Li, Honglei Li, Guojin Li, Yueting Li, Xin-Yue Li, YaJie Li, Dingchen Li, Xiaoling Li, Yanqing Li, Zijian Li, Jixuan Li, Zhandong Li, Xuejie Li, Peining Li, Congjiao Li, Meng-Jun Li, Gaizhen Li, Huilin Li, Liang Li, Songtao Li, Fusheng Li, Huafang Li, Dai Li, Meiyue Li, Nianyu Li, Chenlu Li, Keshen Li, Kechun Li, Yuxin Li, X-L Li, Shaoliang Li, Shawn S C Li, Shu-Xin Li, Hong-Zheng Li, Qun Li, Cuiguang Li, Dongye Li, Tianye Li, Zhen Li, Yuan Li, Chunhong Li, F Li, Mengling Li, Kunpeng Li, Jia-Da Li, Zhenghao Li, Chun-Bo Li, Zhantao Li, Baoqing Li, Pu Li, Xinle Li, Xingli Li, Bingkun Li, Nien-Chi Li, Wuguo Li, Bing-Hui Li, Tiewei Li, Rong-Bing Li, Daniel Tian Li, Jingyong Li, Honggang Li, Rong Li, Shikang Li, Wei-Yang Li, Mingkun Li, Binxing Li, Shi-Ying Li, Ming Xing Li, Zixiao Li, Guixin Li, Quanzhang Li, Ming-Xing Li, Marilyn Li, Da-wei Li, Shishi Li, Bei-Bei Li, Hong-Lian Li, Haitong Li, Xiumei Li, Yuli Li, Melody M H Li, Ruibing Li, Qingfang Li, Peibo Li, Qibing Li, Huanjun Li, Heng Li, Wende Li, Chung-Hao Li, Liuzheng Li, Zhanjun Li, Yifei Li, Tianming Li, Chang-Sheng Li, Xiao-Na Li, Tianyou Li, Jipeng Li, Xidan Li, Yixing Li, Chengcheng Li, Yu-Jin Li, Longxuan Li, Baoting Li, Huiyou Li, Ka Wan Li, Shi-Guang Li, Wenxiu Li, Binbin Li, Xinyao Li, Zhuang Li, Yu-Hao Li, Gui-xing Li, Shilin Li, Niu Li, Shunle Li, Siyue Li, Diyan Li, Mengyao Li, Shili Li, Yixuan Li, Shan-Shan Li, Meiqing Li, Zhuanjian Li, Gerard Li, Yuyun Li, Hengyu Li, Zhiqiong Li, Zonglin Li, Yinhao Li, Pik Yi Li, Junying Li, Jingxin Li, Mufan Li, Chun-Lai Li, Defeng Li, Shiya Li, Zu-guo Li, Xin-Zhu Li, Xiao-Jiao Li, Jia-Xin Li, Kuiliang Li, Pindong Li, Hualian Li, Junhong Li, Youchen Li, W Y Li, Li Li, Hanxue Li, Lulu Li, Yi-Heng Li, Xiaoqin Li, L P Li, Chunmei Li, Runbing Li, Mingjun Li, Yuanhua Li, Qiaolian Li, Yanmin Li, Jingyi Li, Ji-Cheng Li, Yuxiang Li, Haolong Li, Hao-Fei Li, Xuanzheng Li, Peng-li Li, Quan Li, Yining Li, Xue-Ying Li, Xiurong Li, Huijuan Li, Haiyu Li, Xu-Zhao Li, Yunze Li, Yanzhong Li, Guohui Li, Kainan Li, Yongzhe Li, Qingfeng Li, Tianyi Li, Xiaoyan Li, Nanlong Li, Ping Li, Xu-Bo Li, Fangzhou Li, Nien-Chen Li, Yue-Chun Li, Jiahui Li, Huiping Li, Kangyuan Li, Biao Li, Yuanchuang Li, Haiying Li, Yunting Li, Xiaoxuan Li, Anyao Li, Hongliang Li, Qing-Chang Li, Hong-Yan Li, Shengbiao Li, Yue-Rui Li, Ruidong Li, Dalei Li, Zongjun Li, Y M Li, Changqing Li, Hanting Li, Dong-Jie Li, Xiaomin Li, Sijie Li, Dengxiong Li, Meilan Li, D C Li, Andrew C Li, Jianye Li, Yi-Shuan J Li, Tinghao Li, Qiuyan Li, Zhouxiang Li, Tingguang Li, Yun-tian Li, Jianliang Li, Xiangyang Li, Guangzhao Li, Chunjie Li, Yixi Li, Shuyu Dan Li, S A Li, Tianfeng Li, Anna Fen-Yau Li, Minghui Li, Jiangfeng Li, Jinjie Li, Liming Li, Jie-Pin Li, Kaiyi Li, Junyi Li, Dongtao Li, Wenqun Li, Fengyuan Li, Guixia Li, Yinan Li, Aoxi Li, Chenxi Li, Zuo-Lin Li, Yuanjing Li, Zhengwei Li, Linqi Li, Bingjue Li, Xixi Li, Binghu Li, Yan-Chun Li, Suiyan Li, Yu-Hang Li, Qiaoqiao Li, Zhenguang Li, Xiaotian Li, Jia-Ru Li, Shuhui Li, Shu-Hong Li, Pei-Qin Li, Chun-Xiao Li, Shuyue Li, Mengying Li, Quan-Zhong Li, Fangyan Li, Tongzheng Li, Yihong Li, Duo Li, Dali Li, Yaxian Li, Zhiming Li, Xuemei Li, Xueting Li, Hongxia Li, Yongting Li, Danyang Li, Zhenjun Li, Ren Li, Tiandong Li, Hongye Li, Lanfang Li, Mingwei Li, Di-Jie Li, Bo Li, Jinliang Li, Wenxin Li, Qiji Li, W J Li, Zhipeng Li, Zhijia Li, Xiaoping Li, Jingtong Li, Linhong Li, Taoyingnan Li, Lucy Li, Lieyou Li, Zhengpeng Li, Xiayu Li, Huabin Li, Mao Li, Baolin Li, Cuilan Li, Yuting Li, Yongchao Li, Xiaobo Li, Xiaoting Li, Ruotai Li, Meijia Li, Shujiao Li, Yaojia Li, Kun-Ping Li, Xiao-Yao Li, Weirong Li, Weihua Li, Shangming Li, Yibo Li, Yaqi Li, Gui-Hua Li, Zhihong Li, Yandong Li, Runzhao Li, Chaowei Li, Xiang-Dong Li, Huiyuan Li, Yuchun Li, Yingjun Li, Xiufeng Li, Yanxin Li, Xiaohuan Li, Ying-Qin Li, Boya Li, Lamei Li, O Li, Fan Li, Jun Z Li, Joyce Li, Suheng Li, Yiheng Li, Taiwen Li, Hui-Ping Li, Xiaorong Li, Zhiqiang Li, Junru Li, Jiangchao Li, Hecheng Li, Haifeng Li, Changkai Li, Yueping Li, Liping Li, Rena Li, Jiangtao Li, Yu-Jui Li, Zhenglong Li, Yajuan Li, Xuanxuan Li, Rui-Jún Eveline Li, Bing-Mei Li, Yunman Li, Chaoqian Li, Shuhua Li, Yu-Cheng Li, Yirun Li, Chunying Li, Haomiao Li, Weiheng Li, Leipeng Li, Qianqian Li, Baizhou Li, Zhengliang Li, YiQing Li, Han-Ru Li, Sheng Li, Wei-Qin Li, Weijie Li, Guoyin Li, Yaqiang Li, Qingxian Li, Zongyi Li, Dan-Dan Li, Yeshan Li, Qiwei Li, Zirui Li, Yongpeng Li, Chengjun Li, Keke Li, Jianbin Li, Chanyuan Li, Shiying Li, Jianxiong Li, Ji Li, Huaying Li, Tuojian Li, Yixin Li, Ziyue Li, Juntong Li, Zhongzhe Li, Xiang Li, Yumei Li, Xiang-Ping Li, Chaonan Li, Wenqiang Li, Yu-Chia Li, Pei-Shan Li, Zaibo Li, Shaomin Li, Heying Li, Guangming Li, Xuan-Ling Li, Yuxuan Li, Bingshan Li, Xiaoqiang Li, Jiahao Li, Hanxiao Li, Jiansheng Li, Shuying Li, Shibao Li, Pengjie Li, Kunlong Li, Xiaomei Li, Ruijin Li
articles
Yang Zheng, Qiuxuan Li, Yuxiu Yang +4 more · 2025 · Journal of the American Heart Association · added 2026-04-24
Calcific aortic valve stenosis (CAVS) can lead to cardiac adverse outcomes; however, currently, no effective pharmacological interventions are available to prevent or delay disease progression. Emergi Show more
Calcific aortic valve stenosis (CAVS) can lead to cardiac adverse outcomes; however, currently, no effective pharmacological interventions are available to prevent or delay disease progression. Emerging evidence has identified significant associations between CAVS and key biomarkers, including Lp(a) (lipoprotein [a]), low-density lipoprotein cholesterol, and PCSK9 (proprotein convertase subtilisin/kexin type 9). However, robust evidence from randomized controlled trials is still lacking to substantiate these associations. The EPISODE (Effect of PCSK9 Inhibitors on Calcific Aortic Valve Stenosis) trial is a prospective, evaluator-blinded, randomized controlled trial designed to assess the therapeutic efficacy of PCSK9 inhibitors in patients with CAVS. A total of 160 patients with mild-to-moderate or asymptomatic severe CAVS will be randomly assigned to receive either statin monotherapy or a combination of statins and PCSK9 inhibitors. Participants will undergo follow-up assessments at 3-month intervals for 24 months, including transthoracic ultrasonic cardiogram, computed tomography, and quality-of-life evaluations using the EuroQol-5 Dimension-3 Level questionnaire. The primary end point is the annualized change in peak aortic jet velocity, whereas secondary end points encompass changes in aortic valve area, calcification score, incidence of heart valve surgery, and quality of life. Safety end points include all-cause mortality and cardiovascular events. The trial aims to evaluate the efficacy of PCSK9 inhibitors in modulating disease progression, reducing adverse cardiovascular events, and improving clinical outcomes in patients with CAVS. The anticipated findings are expected to provide critical insights for developing novel therapeutic strategies for early intervention in CAVS. URL: https://www.clinicaltrials.gov; Unique Identifier: NCT04968509. Show less
📄 PDF DOI: 10.1161/JAHA.125.042112
LPA
Yi Wen, Hongxia Li, Sydney Smith +9 more · 2025 · Journal of clinical lipidology · Elsevier · added 2026-04-24
Cholesteryl ester transfer protein (CETP) mediates the exchange of triglycerides (TG) from apolipoprotein B (ApoB)-containing lipoproteins to high-density lipoproteins (HDL) and the reciprocal exchang Show more
Cholesteryl ester transfer protein (CETP) mediates the exchange of triglycerides (TG) from apolipoprotein B (ApoB)-containing lipoproteins to high-density lipoproteins (HDL) and the reciprocal exchange of cholesterol (C) from HDL to ApoB-containing lipoproteins. CETP inhibition increases HDL-C and decreases low-density lipoprotein cholesterol (LDL-C) while modestly decreasing TG. Considering that CETP inhibitors block removal of TG from TG-rich lipoproteins (TRL), it is interesting that CETP inhibition decreases TG concentrations. TG levels are largely regulated by lipoprotein lipase (LPL), the enzyme primarily responsible for hydrolyzing TG. The angiopoietin-like 3/8 complex (ANGPTL3/8) is the most potent circulating LPL inhibitor, while the TG-lowering apolipoprotein A5 (ApoA5) acts by suppressing ANGPTL3/8-mediated LPL inhibition. To better understand CETP biology, we studied the effects of CETP overexpression and CETP inhibition on the levels of ANGPTL3/8 and ApoA5 in circulation using dedicated immunoassays. CETP-overexpressing transgenic mice had increased TG and normal ANGPTL3/8 levels but manifested dramatically reduced ApoA5 concentrations. Administration of the CETP inhibitor evacetrapib had no effect on ANGPTL3/8 levels in CETP-overexpressing mice or in humans. However, evacetrapib administration increased ApoA5 concentrations in both species. In human subjects, evacetrapib treatment increased circulating ApoA5 levels in the late-stage ACCELERATE and ACCENTUATE studies by 160.1% and 204.7%, respectively. Our results uncover a previously unrecognized link between CETP and ApoA5 by showing that CETP overexpression reduces ApoA5 levels while CETP inhibition increases ApoA5 concentrations. Show less
no PDF DOI: 10.1016/j.jacl.2025.06.008
APOA5
Wenyong Li, Rudi Lv, Husong Su +4 more · 2025 · Scientific reports · Nature · added 2026-04-24
The Kruppel-like factor 15(KLF15) gene functions as a crucial transcriptional modulator involved in numerous cellular processes such as differentiation, proliferation, growth, and programmed cell deat Show more
The Kruppel-like factor 15(KLF15) gene functions as a crucial transcriptional modulator involved in numerous cellular processes such as differentiation, proliferation, growth, and programmed cell death. The epithelial-to-mesenchymal transition (EMT) provides malignant cells with the adaptability and movement necessary for tumor advancement and spread, with zinc finger E-box binding homeobox 1(ZEB1) playing a pivotal role as a transcriptional factor in EMT. This investigation initially examined the association between the KLF15 protein and EMT associated transcription factors such as ZEB1, Slug, and Snail, along with marker proteins like E-cadherin and β-catenin in bladder cancer. Furthermore, we explored their connections with clinicopathological attributes and conducted prognostic analyses. Immunohistochemical techniques were utilized to ascertain the presence of KLF15 protein and EMT-associated transcription factor proteins, along with their marker proteins in 110 specimens of bladder cancer tissues. Concurrently, clinicopathological data and postoperative survival statistics were amassed. The rates of KLF15 and Slug protein expression were linked with pathological differentiation, lymphatic involvement, and pTNM staging. The protein expression rates of ZEB1, Slug, Snail, E-cadherin, and β-catenin also showed associations with lymphatic metastasis and pTNM stages. Notably, the expression of KLF15, the coexpression of KLF15 and ZEB1, and lymphatic metastasis emerged as independent prognostic indicators for the overall survival rates in bladder cancer cases. EMT enhances the risk of tumor recurrence and reduces overall survival durations in bladder cancer cases. Furthermore, KLF15 is a significant contributor to the EMT pathway in bladder cancer, primarily through its interaction with the transcription factor ZEB1. KLF15 and ZEB1 might serve as key biomarkers for metastasis and prognosis, offering potential new targets for therapeutic intervention in bladder cancer. Show less
no PDF DOI: 10.1038/s41598-025-22698-5
SNAI1
Qing Wang, Wei He, Shilong Han +6 more · 2025 · Cancer medicine · Wiley · added 2026-04-24
Colorectal cancer (CRC) metastasis remains a major cause of mortality, driven by epithelial-to-mesenchymal transition (EMT) and invasion. Programmed cell death 4 (Pdcd4), a tumor suppressor, is known Show more
Colorectal cancer (CRC) metastasis remains a major cause of mortality, driven by epithelial-to-mesenchymal transition (EMT) and invasion. Programmed cell death 4 (Pdcd4), a tumor suppressor, is known to inhibit translation via interaction with eukaryotic initiation factor 4A (eIF4A). Previous studies have established that Pdcd4 suppresses stress-activated protein kinase 1-interacting protein 1 (Sin1) translation through the mTORC2-Akt axis, thereby downregulating Snail expression and EMT in CRC cells. However, whether Pdcd4 directly regulates Slug, another critical EMT transcription factor, remains unexplored. PDCD4 shRNA and SLUG siRNA were used to knock down Pdcd4 and Slug in colorectal cancer cells, respectively. The sucrose gradient fractionation was performed to determine SLUG translation. A luciferase reporter assay was used to determine the role of the SLUG 5' untranslated region (5'UTR) on Pdcd4 inhibition. The effect of Slug on promoting invasion was determined by Matrigel invasion assays. Knockdown of Pdcd4 in colorectal cancer cells increased Slug protein levels without altering SLUG mRNA abundance. Sucrose gradient fractionation revealed that Pdcd4 knockdown elevated the proportion of SLUG mRNA in polysome fractions, demonstrating Pdcd4-mediated suppression of SLUG translation. To validate the mechanism, the SLUG 5'UTR was cloned and fused to a luciferase reporter and named SLUG-5'UTR-Luc. Pdcd4 knockdown markedly enhanced SLUG-5'UTR-Luc activity; whereas, ectopic Pdcd4 expression suppressed it, indicating that the SLUG 5'UTR is critical for Pdcd4-mediated translational repression. Treatment with the eIF4A inhibitor silvestrol substantially reduced Slug protein levels and SLUG-5'UTR-Luc activity. In addition, Pdcd4 overexpression decreased Slug protein abundance and restored E-cadherin expression. Notably, Slug knockdown in Pdcd4-deficient cells rescued E-cadherin expression and abrogated the invasive phenotype. These findings suggest that up-regulation of Slug translation by Pdcd4 knockdown contributes to enhanced invasion. Pdcd4 suppresses colorectal cancer invasion by translationally downregulating Slug expression. Show less
no PDF DOI: 10.1002/cam4.71145
SNAI1
Giuliana Ascone, Rajdeep Kaur, Arwaa Mehran +14 more · 2025 · bioRxiv : the preprint server for biology · Cold Spring Harbor Laboratory · added 2026-04-24
Osteoglophonic Dysplasia (OGD) is an autosomal dominant skeletal dysplasia characterized by impaired bone growth resulting in short stature, severe craniofacial abnormalities, and in some patients FGF Show more
Osteoglophonic Dysplasia (OGD) is an autosomal dominant skeletal dysplasia characterized by impaired bone growth resulting in short stature, severe craniofacial abnormalities, and in some patients FGF23-mediated hypophosphatemia. It is caused by gain-of-function variants in FGFR1, particularly in or near the transmembrane domain of the receptor. We used CRISPR in mice to knock-in the FGFR1 p.N330I variant, chosen based on its association with FGF23 excess. Skeletal phenotyping of this Show less
📄 PDF DOI: 10.1101/2025.11.14.680268
FGFR1
Fang Cheng, Xinyu Niu, Yaoling Wang +3 more · 2025 · Diabetology & metabolic syndrome · BioMed Central · added 2026-04-24
The Glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) are well-established drug targets for the treatment of diabetes and obesity. Studies Show more
The Glucagon-like peptide-1 receptor (GLP-1R) and the glucose-dependent insulinotropic polypeptide receptor (GIPR) are well-established drug targets for the treatment of diabetes and obesity. Studies have linked GLP-1R agonist to cardiometabolic diseases (CMDs), while the therapeutic potential of the GIPR agonist remains a topic of debate. Using genetic variants as instrumental variables, we performed a two-sample Mendelian randomization (MR) analysis to investigate causal relationships between genetically proxied GIPR agonist and 23 CMD outcomes, and a two-step mediation analysis to identify mediating inflammatory biomarkers. The inverse variance weighted (IVW) method served as the primary analytical approach, supplemented by sensitivity analyses to validate robustness. The genetic mimicry of GIPR enhancement showed significant protective associations with 14 CMDs. Mediation analysis revealed that Fms-related tyrosine kinase 3 ligand (Flt3L) partially mediated the effects of GIPR agonist on angina (OR 0.997 [0.995-0.999], P = 0.0048) and myocardial infarction(MI) (OR 0.998 [0.996-0.999], P = 0.0077), accounting for 15.49% and 16.71% of the total risk reduction, respectively. Our study revealed that GIPR agonist lowers the risk of 14 CMDs. Flt3L is pinpointed as a key mediating factor in reducing angina and MI risk, suggesting a new therapeutic avenue. Show less
📄 PDF DOI: 10.1186/s13098-025-01744-2
GIPR
Y X Li, H X Peng, H D Guo +11 more · 2025 · Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi · added 2026-04-24
With the advancement of genomic technologies, precision lifestyle interventions tailored to individual genetic backgrounds have emerged as a novel approach for preventing and managing chronic diseases Show more
With the advancement of genomic technologies, precision lifestyle interventions tailored to individual genetic backgrounds have emerged as a novel approach for preventing and managing chronic diseases such as obesity. Several randomized controlled trials (RCTs) targeting obese or overweight populations have found that individuals with different genotypes exhibit varying responses to the same lifestyle intervention (gene-lifestyle intervention interactions). To date, more than 20 genes, including Show less
no PDF DOI: 10.3760/cma.j.cn112338-20250501-00297
MC4R
Yanping Wang, Xiaoru Ma, Zhixin Qiao +16 more · 2025 · Journal of neuroinflammation · BioMed Central · added 2026-04-24
Astrocytes are key regulators of neuroinflammation in multiple sclerosis (MS). Electroacupuncture (EA), a safe and cost-effective adjuvant therapy, has shown benefits in neurodegenerative diseases, bu Show more
Astrocytes are key regulators of neuroinflammation in multiple sclerosis (MS). Electroacupuncture (EA), a safe and cost-effective adjuvant therapy, has shown benefits in neurodegenerative diseases, but its astrocyte-related mechanisms remain unclear. Here, we demonstrated that EA at ST36 alleviated blood-brain barrier (BBB) disruption and neuroinflammation during the peak period of experimental autoimmune encephalomyelitis (EAE). Additionally, EA at ST36 upregulated the expression of α-melanocyte-stimulating hormone (α-MSH) and its receptor melanocortin-4 receptor (MC4R) in spinal astrocytes. Pharmacological studies showed that MC4R agonist RO27-3225 mimicked the therapeutic effects of EA, whereas MC4R antagonist TCMCB07 weakened EA-mediated BBB protection and neuroinflammation suppression. Moreover, astrocyte-specific silencing of MC4R via adeno-associated virus (AAV) weakened EA-mediated BBB protection and neuroinflammation suppression. RNA-sequencing (RNA-seq) and western blot (WB) revealed that EA exerts neuroprotective effects by activating MC4R to inhibit MAPK and NF-κB signaling pathways. Moreover, in MC4R-overexpressing astrocytes, α-MSH and RO27-3225 reduced inflammation responses, while TCMCB07 reversed the effects by MAPK/NF-κB signaling pathways. Collectively, our findings identify astrocytic MC4R as a critical mediator of EA-driven neuroprotection by suppressing MAPK/NF-κB signaling, providing mechanistic insight and a promising therapeutic target for EAE and other neuroinflammatory disorders. Show less
📄 PDF DOI: 10.1186/s12974-025-03667-1
MC4R
Fei Lu, Lan Li, Li Wang +6 more · 2025 · Discover oncology · Springer · added 2026-04-24
This study aims to comprehensively analyze the genetic characteristics and prognostic value of stemness- and epithelial-mesenchymal transformation (EMT)-related gene signatures in lung adenocarcinoma Show more
This study aims to comprehensively analyze the genetic characteristics and prognostic value of stemness- and epithelial-mesenchymal transformation (EMT)-related gene signatures in lung adenocarcinoma (LUAD). The RNA-sequencing transcriptome profiling data and corresponding clinical information of LUAD were procured from TCGA-LUAD and GEO datasets. After screening, we first obtained 1488 stemness- and EMT-related genes. Then 304 hub genes were obtained via WGCNA, of which 52 genes were established to be prognosis-related hub genes. Thereafter, a prognostic model containing 11 genes (ANGPTL4, CCL20, ENO1, FGF2, LGR4, PIM2, S100P, SATB2, SHOX2, ZNF322, and CFTR) was constructed. We demonstrated that a higher risk score was an independent negative prognostic factor in LUAD patients. A nomogram was further constructed to better predict the survival of LUAD patients. More importantly, we found that the low-risk group has a more favorable anti-tumor immune microenvironment and may benefit more from immunotherapy. We finally noticed that the high-risk group was more sensitive to most drugs including drugs commonly used to treat LUAD patients. In conclusion, this study has summarized the alterations and prognostic role of stemness- and EMT-related gene signatures in LUAD and constructed a prognostic model to accurately and stably predict survival and guide individualized treatment decisions. Show less
📄 PDF DOI: 10.1007/s12672-025-02866-9
ANGPTL4
Chongyang Cai, Leipeng Li, Xiaohuan Lv +12 more · 2025 · Nature communications · Nature · added 2026-04-24
Lanthanides-doped luminescent materials have gathered considerable attention due to their application potential in stress sensing, lighting and display, anti-counterfeiting technology and so forth. Ho Show more
Lanthanides-doped luminescent materials have gathered considerable attention due to their application potential in stress sensing, lighting and display, anti-counterfeiting technology and so forth. However, existing materials mainly cover the 380-1540 nm range, with slight extension to the UV region, impeding their applications in solar-blind imaging, background-free tracking, concealed communication, etc. To address this challenge, here we propose guidelines for far-UVC (200-230 nm) optical design. Accordingly, we achieve multi-stimulated far-UVC luminescence at ~222 nm in Pr Show less
📄 PDF DOI: 10.1038/s41467-025-61522-6
LPL
Yunxi Li, In-Hee Lee, Sek Won Kong · 2025 · medRxiv : the preprint server for health sciences · Cold Spring Harbor Laboratory · added 2026-04-24
Despite widely acknowledged sex differences in lipid metabolism and risks for cardiovascular disease, genetic associations contributing to such differences remain incompletely characterized. Here, we Show more
Despite widely acknowledged sex differences in lipid metabolism and risks for cardiovascular disease, genetic associations contributing to such differences remain incompletely characterized. Here, we performed a sex-stratified genome-wide association study (GWAS) for four lipid profiles to identify loci exhibiting differential effects between males and females. Using whole-genome sequencing data from All of Us Research Program comprising 124,920 participants of diverse ancestry, we conducted GWAS analyses separately in males, females, and a pooled cohort. Our analyses validated previous findings on genes associated with lipid metabolism. In addition, we have found 5 genes showing significant sex-heterogeneous effects, including Show less
no PDF DOI: 10.1101/2025.11.21.25340771
ZPR1
Wanshi Li, Weiwei Pei, Yiwei Wang +16 more · 2025 · British journal of cancer · Nature · added 2026-04-24
In recent years, there has been a steady increase in professionals engaged in radioactive work. The biological impacts of long-term exposure to low dose-rate radiation remain elusive, as there is a de Show more
In recent years, there has been a steady increase in professionals engaged in radioactive work. The biological impacts of long-term exposure to low dose-rate radiation remain elusive, as there is a dearth of systematic research in this field. BEAS-2B cells were used to establish a cell model with continuous passaging after radiation exposure, which was subsequently subjected to in vivo tumorigenesis assays and in vitro malignant phenotype experiments. By scRNA-seq, we conducted copy number variation analysis, cell trajectory analysis, and cell communication analysis. Furthermore, we used FACS, molecular docking, multiplex immunohistochemistry, qRT-PCR, and co-immunoprecipitation to validate and further explore the molecular mechanisms driving tumor evolution. Long-term low dose-rate exposure is associated with a higher degree of malignancy, as evidenced by the induction of more CNV and EMT events, as well as the delayed activation of DNA repair pathways, which trigger increased genomic instability. The long-term low dose-rate specific ligand-receptor pair, ANGPTL4-SDC4, enhances cell malignancy by promoting angiogenesis in newly formed lung tumor cells. This study not only provides the first evidence and mechanistic explanation that long-term low dose-rate radiation leads to increased cellular malignancy but also offers valuable theoretical insights into the dynamic processes of early tumor evolution in lung cancer within the realm of tumor biology. Show less
no PDF DOI: 10.1038/s41416-025-03128-9
ANGPTL4
Hongxin Cheng, Qing Zhang, Wen Zhong +6 more · 2025 · Signal transduction and targeted therapy · Nature · added 2026-04-24
Atherosclerosis serves as the core pathological basis of cardiovascular, cerebrovascular, and peripheral arterial diseases, posing a serious threat to human health. However, current mainstream treatme Show more
Atherosclerosis serves as the core pathological basis of cardiovascular, cerebrovascular, and peripheral arterial diseases, posing a serious threat to human health. However, current mainstream treatments such as statin drugs and stent implantation are associated with significant side effects or limited efficacy, highlighting the urgent need for new therapeutic strategies. Pulsed electromagnetic fields (PEMFs), due to their noninvasive nature and anti-inflammatory properties, show potential in the treatment of atherosclerosis. This study utilized ApoE-/- mice, ApoE-/-NLRP3-/- knockout mice, human umbilical vein endothelial cells (HUVECs), human aortic endothelial cells (HAECs), and human plasma samples for experiments, revealing significant endothelial cell (EC) inflammation and pyroptosis during the progression of atherosclerosis. PEMFs were found to effectively inhibit the activation of the NLRP3 inflammasome, reduce plaque formation, and delay the progression of atherosclerosis. Proteomic analysis of plasma from atherosclerosis patients further indicated elevated expression levels of proteins related to inflammation and pyroptosis, with particularly notable changes in membrane proteins. Mechanistic studies demonstrated that PEMFs improve mitochondrial dysfunction in ECs by regulating membrane tension and the mechanosensitive tension-mediated transient receptor potential vanilloid 4 (TRPV4) channels, thereby reducing pyroptosis. This discovery not only reveals a novel mechanobiological pathway but also provides a solid theoretical foundation for the development of PEMF-based therapies for atherosclerosis. Schematic diagram of the mechanism by which PEMFs treat atherosclerosis (created in BioRender). Wei, B. (2025) https://BioRender.com/undefined ). Show less
📄 PDF DOI: 10.1038/s41392-025-02479-2
APOE
Nafeisha Simayi, Jiaying Li, Junkai Hu +4 more · 2025 · Frontiers in immunology · Frontiers · added 2026-04-24
Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase i Show more
Tumor angiogenesis is required for the progression of non-small cell lung cancer (NSCLC), and anti-vascular endothelial growth factor (anti-VEGF) antibody bevacizumab and multitarget tyrosine kinase inhibitor anlotinib are anti-cancer treatment options, the combined effect of which in NSCLC remains unclear. A vascularized microfluidic chip was applied to model angiogenesis, together with Bevacizumab plus anlotinib (B+A) inhibited angiogenesis, reducing vessel density to 10% of control values and also reducing diameter and green fluorescent protein (GFP) area ratio. B+A inhibited cell viability by 78%, colony formation by 90%, and invasion by 75% in NSCLC cell lines A549 and H1299; downregulated N-cadherin 5.34-fold, vimentin 6.46-fold, and α-SMA 4.35-fold; and upregulated E-cadherin 3.75-fold. The rates of apoptosis of A549 and H1299 cells were increased 3.85-fold. The phosphorylation of VEGFR2, PDGFRβ, and FGFR1 was also reduced. B+A reduced tumor volume 7.23-fold and weight 7.08-fold, decreased tumor cell density, and lowered Ki-67 expression in an HIF-1α inhibitor PX478 did not enhance the anti-tumor effects of B+A, but HIF-1α activator DMOG reversed them. In addition, the combination therapy enhanced CD4 Show less
📄 PDF DOI: 10.3389/fimmu.2025.1613368
FGFR1
Fenglou He, Han Liu, Yakun Yao +6 more · 2025 · International journal of molecular sciences · MDPI · added 2026-04-24
This study aimed to collaboratively investigate the mechanism of variations in intramuscular fat (IMF) content in Wandong cattle using transcriptomics and metabolomics techniques. Longissimus dorsi (L Show more
This study aimed to collaboratively investigate the mechanism of variations in intramuscular fat (IMF) content in Wandong cattle using transcriptomics and metabolomics techniques. Longissimus dorsi (LD) muscle samples were collected from thirteen free-range Wandong cattle in Fengyang County, Anhui Province, China. From this initial cohort, eight animals closely matched in age and body weight were selected. Based on IMF content measured by Soxhlet extraction, these eight cattle were divided into two groups: the high-IMF (HF, n = 4) and low-IMF (LF, n = 4) groups. Subsequent analyses were performed on integrated datasets comprising the transcriptome, metabolome, and fatty acid profile. The results revealed a significant increase in IMF in the HF group compared to the LF group ( Show less
📄 PDF DOI: 10.3390/ijms262311557
HSD17B12
Xueying Fan, Baoting Li, Fan Zhang +4 more · 2025 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · Wiley · added 2026-04-24
Liver and lung are the most common metastatic sites in colorectal cancer (CRC), where the tumor microenvironment (TME) plays a crucial role in the progression and metastasis of CRC. Understanding the Show more
Liver and lung are the most common metastatic sites in colorectal cancer (CRC), where the tumor microenvironment (TME) plays a crucial role in the progression and metastasis of CRC. Understanding the interactions between various types of cells in the TME can suggest innovative therapeutic strategies. Using single-cell RNA sequencing (scRNA-Seq) and clinical samples, fibroblast growth factor-19 (FGF19, rodent FGF15) is found to mediate a significant interaction between CRC cells and cancer-associated fibroblasts (CAFs), activating the hepatic stellate cells (HSCs)-to-CAFs differentiation. In various CRC metastatic mouse models, it is shown that FGF15 has a more pronounced effect on liver metastasis compared to pulmonary metastasis. More importantly, the differentially expressed genes (DEGs) are also identified from the RNA-Seq dataset upon the activation of HSCs by FGF19 and compared the DEGs in matched primary and metastatic mRNA samples from patients with CRC liver metastasis (CRCLM), it is found that the ANGPTL4 gene is significantly associated with HSCs activation. Different mouse models also demonstrated the impact of the FGF19/ANGPTL4 axis on the severity of CRCLM. Importantly, disruption of this axis significantly inhibits CRCLM in vivo. This study is among the first to demonstrate the impact of the FGF19/ANGPTL4 axis on CRCLM, offering a novel therapeutic strategy. Show less
📄 PDF DOI: 10.1002/advs.202413525
ANGPTL4
Ting He, Jinbo Zhao, Ling Hou +2 more · 2025 · International journal of general medicine · added 2026-04-24
Coronary heart disease (CHD) has a significant co-morbid association with chronic kidney disease (CKD), but identification tools for the risk of concomitant CKD in patients with CHD are still lacking. Show more
Coronary heart disease (CHD) has a significant co-morbid association with chronic kidney disease (CKD), but identification tools for the risk of concomitant CKD in patients with CHD are still lacking. The purpose of this research was to construct machine learning (ML) models for identifying undetected CKD in CHD patients. 1786 CHD patients undergoing coronary intervention were retrospectively included. Lasso regression and multifactor logistic regression were used to screen feature variables. Five ML models, ie, logistic regression (LR), support vector machine (SVM), random forest (RF), gradient boosting machine (GBM), and extreme gradient boosting (XGBoost), were constructed. Participants were divided into the training set and validation set in a 7:3 ratio. The evaluation metrics included the area under the curve, calibration curve, and decision curve. Totally, 1786 CHD patients were enrolled and split into training (70%) and validation (30%) sets. The prevalence of CKD was 21.8% (390/1786). Multivariate logistic regression analysis showed that men, advanced age, hypertension, diabetes mellitus, history of atrial fibrillation (AF), high Gensini, low hemoglobin, low plateletcrit (PCT), high triglycerides (TG), high lipoprotein(a) (Lp(a)), hyperkalemia, high uric acid to albumin ratio (UAR), high systemic inflammation response index (SIRI), low lymphocyte to monocyte ratio (LMR), and high apolipoprotein B to apolipoprotein A1 (ApoB/ApoA1) ratio were the key clinical and laboratory test indicators of CKD. The XGBoost model performed optimally in the validation set (AUC=0.909, 95% CI 0.881 -0.937). SHapley Additive explanation analysis identified UAR, hypertension, Gensini score, age, and SIRI as the top 5 key features. The XGBoost model constructed on routine clinical data was effective in identifying CKD risk in CHD patients, with UAR as a novel strong predictor. Decision curve analysis confirmed the clinical utility of the model, indicating that it may be used to guide decisions for enhanced monitoring and early intervention over a wide range of risk thresholds. Show less
📄 PDF DOI: 10.2147/IJGM.S558568
APOB
Xiaoqiang Wei, Lihui Wang, Haiwang Zhang +6 more · 2025 · Frontiers in microbiology · Frontiers · added 2026-04-24
Forage scarcity during the cold season poses a major challenge to livestock farming on the Qinghai-Tibet Plateau. Jerusalem artichoke (
📄 PDF DOI: 10.3389/fmicb.2025.1699658
LPL
Kang-Fu Yin, Ting Chen, Xiao-Jing Gu +8 more · 2025 · Molecular neurobiology · Springer · added 2026-04-24
Current research lacks comprehensive investigations into the potential causal link between mitochondrial-related genes and the risk of neurodegenerative diseases (NDDs). We aimed to identify potential Show more
Current research lacks comprehensive investigations into the potential causal link between mitochondrial-related genes and the risk of neurodegenerative diseases (NDDs). We aimed to identify potential causative genes for five NDDs through an examination of mitochondrial-related gene expression levels. Through the integration of summary statistics from expression quantitative trait loci (eQTL) datasets (human blood and brain tissue), mitochondrial DNA copy number (mtDNA-CN), and genome-wide association studies (GWAS) datasets of five NDDs from European ancestry, we conducted a Mendelian randomization (MR) analysis to explore the potential causal relationship between mitochondrial-related genes and Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Lewy body dementia (LBD). Sensitivity analysis and Bayesian colocalization were employed to validate this causal relationship. Through MR analysis, we have identified potential causal relationships between 12 mitochondria-related genes and AD, PD, ALS, and FTD overlapping with motor neuron disease (FTD_MND) in human blood or brain tissue. Bayesian colocalization analysis further confirms 9 causal genes, including NDUFS2, EARS2, and MRPL41 for AD; NDUFAF2, MALSU1, and METTL8 for PD; MYO19 and MRM1 for ALS; and FASTKD1 for FTD_MND. Importantly, in both human blood and brain tissue, NDUFS2 exhibits a significant pathogenic effect on AD, while NDUFAF2 demonstrates a robust protective effect on PD. Additionally, the mtDNA-CN plays a protected role in LBD (OR = 0.62, p = 0.031). This study presents evidence establishing a causal relationship between mitochondrial dysfunction and NDDs. Furthermore, the identified candidate genes may serve as potential targets for drug development aimed at preventing NDDs. Show less
no PDF DOI: 10.1007/s12035-024-04528-3
MYO19
Yi Han, Yun Hong, Yan Gao +11 more · 2025 · PLoS genetics · PLOS · added 2026-04-24
Heart failure (HF) is a serious cardiovascular condition resulting from abnormalities in multiple biological processes, affecting over 64 million people worldwide. We sought to expand our understandin Show more
Heart failure (HF) is a serious cardiovascular condition resulting from abnormalities in multiple biological processes, affecting over 64 million people worldwide. We sought to expand our understanding of the genetic basis of HF and more specific NICM subtype in the East Asian populations and evaluate the biological pathways underlying subclinical left ventricular dysfunction. We conducted a meta-analysis of genome-wide association studies (GWAS) for all-cause HF in the East Asian populations (N cases ~ 13,385) and a more precise definition of nonischemic cardiomyopathy (NICM) subtype in multi-ancestry populations (N cases~3,603). We identified a low-frequency East-Asian enriched coding variant near MYBPC3 and a NICM specific locus. Follow up analyses demonstrated male-specific HF association at the MYBPC3 locus, and highlighted SVIL as a candidate causal gene for NICM. Moreover, we demonstrated that SVIL deficiency aggravated cardiomyocyte hypertrophy, apoptosis and impaired cell viability in phenylephrine (PE)-treated H9C2 cells. In addition, the gene expression level of B-type natriuretic peptide (BNP) which was deemed as a hallmark for HF was further elevated by SVIL silencing in PE-stimulated H9C2 cells. RNA-sequencing analysis of H9C2 cells revealed that the function of SVIL might be mediated through pathways relevant to regulation and differentiation of heart muscle. These results enhance our understanding of the genetic architecture of HF in the East Asian populations, and provide important insight into the biological pathways underlying NICM and sex-specific relevance of the MYBPC3 locus that warrants further replication in another datasets. Show less
📄 PDF DOI: 10.1371/journal.pgen.1011897
MYBPC3
Yanting Zhang, Fei Cheng, Lixia Li · 2025 · Medicine · added 2026-04-24
Prostate cancer is epithelial malignant prostate hyperplasia caused by a tumor. We found prostate cancer GSE141551 and GSE200879 profiles from gene expression omnibus database, followed by differentia Show more
Prostate cancer is epithelial malignant prostate hyperplasia caused by a tumor. We found prostate cancer GSE141551 and GSE200879 profiles from gene expression omnibus database, followed by differentially expressed genes (DEGs) analysis, weighted gene co-expression network analysis, protein-protein interaction analysis, gene function enrichment analysis, and comparative toxicology database analysis. Finally, the gene expression heat map was drawn, and miRNA information regulating core DEGs was retrieved. A total of 1151 DEGs were found, most of them focusing on systematic development, cell development, cell differentiation, regulation of multicellular biological processes, anatomical morphogenesis, MAPK signaling pathway, proteoglycans in cancer, fluid shear stress, and atherosclerosis. The core genes (MYL9, TAGLN, SMTN, CNN1, MYH11, MYLK, MYOCD, ACTC1, LMOD1, and TPM2) obtained in end are all lowly expressed in prostate cancer samples and are associated with hypertension, tumor metastasis, prostate tumors, and tumor aggressiveness. LMOD1 and SMTN are lowly expressed in prostate cancer and may be used as markers in prostate cancer nursing. Show less
📄 PDF DOI: 10.1097/MD.0000000000041357
LMOD1
Ruijun Sun, Yuchi Zhang, Jingying Xu +7 more · 2025 · Archiv der Pharmazie · Wiley · added 2026-04-24
Acetylcholinesterase (AChE) inhibitors are crucial for the symptomatic management of Alzheimer's disease (AD), with natural products-particularly botanical sources like Yellow Gastrodia elata (YGE)-se Show more
Acetylcholinesterase (AChE) inhibitors are crucial for the symptomatic management of Alzheimer's disease (AD), with natural products-particularly botanical sources like Yellow Gastrodia elata (YGE)-serving as promising reservoirs of such inhibitors. Nevertheless, comprehensive screening and mechanistic characterization of their inhibitory potential remain limited. This study sought to identify potent AChE inhibitors from YGE, investigate their mechanisms of action, and assess their therapeutic prospects for AD. Methodologically, an integrated approach was employed, combining ultrafiltration-liquid chromatography (UF-LC) for rapid inhibitor screening, molecular docking and dynamics simulations for mechanistic insight, two-stage high-speed countercurrent chromatography for compound isolation, enzyme kinetics to delineate inhibition modalities, and network pharmacology to uncover relevant AD-related targets. The findings identified seven active constituents with notable AChE inhibition, among which parishins A and G were obtained at high purity (98.26% and 97.26%, respectively) and exhibited mixed-type inhibition with low IC Show less
no PDF DOI: 10.1002/ardp.70174
BACE1
Shoudi Hu, Zihan Shan, Xintong Shen +5 more · 2025 · BMC women's health · BioMed Central · added 2026-04-24
Perimenopause is a critical turning point in women's life cycle, and the issue of sleep disturbance during perimenopause not only affects individual health, but also has profound implications for fami Show more
Perimenopause is a critical turning point in women's life cycle, and the issue of sleep disturbance during perimenopause not only affects individual health, but also has profound implications for family functioning, socioeconomic status, and public health policies. Therefore, this study aims to explore different potential profiles of sleep quality in perimenopausal women in the community and analyze the influencing factors of different profiles. A cross-sectional study was conducted from July 2024 to December 2024, and a total of 281 perimenopausal women in the community were recruited from 4 communities in Bengbu by convenience sampling. The participants completed the pittsburgh sleep quality index (PSQI), and self-rating anxiety scale (SAS), self-rating depression scale (SDS) and simplified coping style questionnaire (SCSQ). Latent profile analysis(LPA) was employed to identify latent profiles of sleep quality of perimenopausal women in the community. The predictors of sleep quality in different latent profiles were assessed via multinomial logistic regression analysis. One-way ANOVA, chi-square test or Fisher exact test, and the Kruskal-Walis test were used to compare the PSQI scores of perimenopausal women in the community under different latent profile characteristics. The mean age of 281 perimenopausal women was 50.09 ± 5.08 years, and the prevalence of sleep disorders was 31.3%. The sleep quality of perimenopausal women in community could be divided into three different latent profiles: good sleep quality group (68.7%), falling sleep and maintenance difficulty group (24.2%), and poor sleep quality with sleep disorder group (7.1%). Taking the good sleep quality group as the reference group, drinking history (OR = 2.061), chronic disease history (OR = 2.154), spouse's health status (OR = 1.871) and anxiety (OR = 4.390) were the risk factors to predict the difficulty in falling asleep and maintaining sleep in community perimenopausal women (P < 0.05). Spouse's health status (OR = 2.139) and anxiety (OR = 19.029) were the risk factors for poor sleep quality and sleep disorders in community perimenopausal women (P < 0.05). There are three qualitatively different potential profile categories of sleep quality in perimenopausal women in the community, and drinking history, chronic disease, poor spouse health and anxiety have predictive effects on their profile categories. In the future, community nursing staff can take targeted interventions according to different categories of sleep quality in perimenopausal women to improve sleep quality and level of health promotion. Show less
📄 PDF DOI: 10.1186/s12905-025-04217-w
LPA
Beibei Bie, Hong Bai, Yingnan Li +2 more · 2025 · IUBMB life · Wiley · added 2026-04-24
G-patch domain-containing protein 2 (GPATCH2), a member of the G-patch domain-containing family, has been implicated in tumor cell growth, but the link between GPATCH2 and hepatocellular carcinoma (HC Show more
G-patch domain-containing protein 2 (GPATCH2), a member of the G-patch domain-containing family, has been implicated in tumor cell growth, but the link between GPATCH2 and hepatocellular carcinoma (HCC) remains uncertain. In the current study, comprehensive bioinformatics analysis revealed that GPATCH2 was markedly upregulated in HCC and positively correlated with aggressive clinicopathological features, including histologic grade, AFP, albumin level, and adjacent hepatic tissue inflammation, as well as miserable outcomes in HCC. GPATCH2 also has certain diagnostic value for HCC, histologic grade, and 1-, 3-, and 5-year survival outcomes. Functionally, loss-of-function experiments disclosed that silencing GPATCH2 suppressed HCC cell proliferation, migration, invasion, and xenograft tumor growth in the subcutaneous mouse model. Silencing GPATCH2 also resulted in an increase in the expression level of CDH1, while causing a decrease in the expression levels of FN1, TWIST1, SNAI1, and SNAI2. Rescue experiments further confirmed SNAI2 as a critical downstream effector mediating GPATCH2-driven oncogenic activity in HCC. Mechanistically, GPATCH2 was uncovered to be transcriptionally activated by the transcription factor Yin Yang 1 (YY1), and can mediate the role of YY1 in promoting HCC progression and elevating SNAI2 expression. Taken together, GPATCH2 is a YY1-regulated oncogenic driver that promotes HCC advancement through SNAI2, highlighting its potential as a diagnostic, prognostic, and therapeutic target for HCC. Show less
no PDF DOI: 10.1002/iub.70070
SNAI1
Xiangyang Li, Xiaomin Zhang, Nina Wei +2 more · 2025 · Frontiers in pharmacology · Frontiers · added 2026-04-24
Hyperlipidemia and its associated hepatic steatosis pose significant global health burdens, necessitating novel therapeutic strategies. High-fat diet (HFD)-fed C57BL/6 mice received TAC (2.5, 5.0, 10. Show more
Hyperlipidemia and its associated hepatic steatosis pose significant global health burdens, necessitating novel therapeutic strategies. High-fat diet (HFD)-fed C57BL/6 mice received TAC (2.5, 5.0, 10.0 g/L) or simvastatin for 2 weeks. Metabolic parameters, serum lipid profiles, hepatic function markers, and histopathology were systematically analyzed. Molecular pathways were interrogated through qPCR, Western blot, and pharmacological inhibition of AMPK (Compound C) and PPARα (GW6471). TAC treatment demonstrated significant dose-dependent improvements across multiple parameters. Compared to HFD controls, TAC reduced body weight by 21.3% and liver index by 18.7%, while lowering fasting blood glucose levels by 32.4%. Serum analyses showed substantial reductions in total cholesterol (46.2%), triglycerides (38.5%), and LDL-cholesterol (52.1%), accompanied by a 29.8% increase in HDL-cholesterol. Hepatic function improved markedly, with ALT and AST levels decreasing by 57.3% and 49.6% respectively. Histopathological examination revealed a 68.4% reduction in hepatic lipid accumulation. At the molecular level, TAC treatment resulted in a 2.7-fold increase in AMPK phosphorylation while significantly reducing HMGCR expression by 63.1% and nuclear SREBP-1c levels by 71.5%. Concurrently, TAC upregulated PPARα and LXRα expression by 3.1-fold and 2.4-fold respectively, leading to enhanced expression of lipolytic enzymes LPL and HL by 2.8-fold and 2.1-fold. These beneficial effects were completely abolished by co-treatment with pathway-specific inhibitors. TAC ameliorates hyperlipidemia and hepatic steatosis through dual modulation of AMPK/SREBP-1c-mediated lipid synthesis and PPARα/LXRα-driven lipolysis, presenting a multifaceted therapeutic approach for metabolic disorders. Show less
📄 PDF DOI: 10.3389/fphar.2025.1662325
LPL
Yujiao Zhao, Luyang Ma, Weijun Li +9 more · 2025 · BMC pregnancy and childbirth · BioMed Central · added 2026-04-24
To investigate longitudinal changes in pelvic floor support in primiparous women with pelvic organ prolapse (POP) after vaginal delivery, focusing on single- and multiple-compartment involvement. Two Show more
To investigate longitudinal changes in pelvic floor support in primiparous women with pelvic organ prolapse (POP) after vaginal delivery, focusing on single- and multiple-compartment involvement. Two hundred primiparas after vaginal delivery were prospectively enrolled and underwent pelvic floor MRI at six weeks postpartum. POP was diagnosed and classified into subgroups (single or multiple compartments involved) based on MRI findings. Primiparas with POP underwent repeat MRI at four months postpartum. Pelvic floor measurements, including injury score and functional parameters of the levator ani muscle (puborectal hiatus line, H line; muscular pelvic floor relaxation line, M line; levator hiatus area, LHA; iliococcygeus angle, ICA; levator plate angle, LPA), were assessed on MRI. Measurements were compared among POP subgroups and a normal control group (without POP) at six weeks postpartum. Additionally, changes between six weeks and four months postpartum were analyzed within POP subgroups. Based on MRI criteria, approximately 41.5% of primiparas were diagnosed with POP, predominantly cystoceles commonly associated with uterine prolapse. Functional parameters of the levator ani, except for LPA at rest, were significantly increased in POP subgroups compared to controls. At four months postpartum, M line, H line, and LPA significantly decreased, and prolapsed organs were elevated in cases with multiple compartments involved, compared to six weeks postpartum. No significant changes were observed in cases with single-compartment involvement during follow-up. A substantial proportion of primiparas experienced postpartum POP. Impaired levator ani function contributed to POP. Pelvic floor support improved during early postpartum in cases with multiple-compartment involvement. Show less
📄 PDF DOI: 10.1186/s12884-025-08044-7
LPA
Chunqing Li, Longting Wu, Fang Hu +2 more · 2025 · Ecology and evolution · Wiley · added 2026-04-24
Understanding the adaptive evolution of brain function in extreme environments remains a central challenge in evolutionary biology. This study investigates the molecular mechanisms underlying cave ada Show more
Understanding the adaptive evolution of brain function in extreme environments remains a central challenge in evolutionary biology. This study investigates the molecular mechanisms underlying cave adaptation by comparing brain transcriptomes of sympatric cave-dwelling ( Show less
📄 PDF DOI: 10.1002/ece3.72652
ADCY3
Rongqing Li, Zikai Zhang, Xin Zhang +6 more · 2025 · BMC neurology · BioMed Central · added 2026-04-24
Symptom burden in primary brain tumor patients varies, emphasizing the need for comprehensive understanding to improve patient care. This study aims to identify distinct symptom clusters among brain t Show more
Symptom burden in primary brain tumor patients varies, emphasizing the need for comprehensive understanding to improve patient care. This study aims to identify distinct symptom clusters among brain tumor patients in Shanghai, China, using Latent Profile Analysis (LPA) to guide personalized diagnosis, treatment, and supportive care. A longitudinal study was conducted among 161 patients with primary brain tumors in Shanghai. Participants completed the MD Anderson Symptom Inventory Brain Tumor Module (MDASI-BT) at three intervals: the day of admission (T1), three days after surgery (T2), and two weeks after surgery (T3). Latent Profile Analysis (LPA) was used to identify subgroups with unique symptom patterns. Six distinct subgroups were identified (entropy = 0.964), ranging from low-burden to persistently severe patterns. Subgroup membership was partially associated with age, tumor grade, and diagnosis. These subgroups were: transient postoperative burden group, stable symptom with cognitive emergence group, distress-predominant, low burden group, elderly-high grade, persistently severe group, nausea-dominant recovery group, and distress-plus-nausea, younger urban group. Our findings reveal substantial heterogeneity in perioperative symptom experiences among brain tumor patients. Identifying subgroups with high and persistent symptom burden may help clinicians target interventions such as enhanced education, proactive monitoring, rehabilitation, psychological support, and antiemetic management. This subgroup-based approach may improve quality of life, reduce morbidity, and guide precision supportive care in neuro-oncology. Show less
📄 PDF DOI: 10.1186/s12883-025-04595-6
LPA
Hualing Li, Junjie Wei, Zhiyi Zheng +6 more · 2025 · Free radical biology & medicine · Elsevier · added 2026-04-24
The established body of knowledge attests to the pivotal influence of ANGPTL4 on lipid metabolism and vascular biology. Nevertheless, its potential implication in neurodegenerative disease remains to Show more
The established body of knowledge attests to the pivotal influence of ANGPTL4 on lipid metabolism and vascular biology. Nevertheless, its potential implication in neurodegenerative disease remains to be fully characterized. The present investigation delves into the involvement of ANGPTL4 in the pathological progression of PD, both in vitro and in vivo. PD models were induced by intraperitoneal administration of MPTP and LPS in WT and ANGPTL4 The observations unveiled that ANGPTL4 deficiency exacerbated behavioral aberrations, intensified dopaminergic neuron loss, and stimulated microglial activation along with p21-dependent senescence. There was an elevation in the expression of proinflammatory cytokines in the PD model. Furthermore, the administration of rANGPTL4 protein reversed the observed phenotypes in ANGPTL4 Our findings posit a salutary role for ANGPTL4 in counteracting PD, rendering it a prospective therapeutic target for the development of innovative drugs aimed at treating neuroinflammation-associated neurological diseases, including PD. Show less
no PDF DOI: 10.1016/j.freeradbiomed.2024.12.009
ANGPTL4
Yiqiao Wang, Shihao Huang, Yangbai Cai +5 more · 2025 · Biochimica et biophysica acta. Molecular basis of disease · Elsevier · added 2026-04-24
Programmed cell death protein 5 (PDCD5) is involved in apoptosis and is regarded as a tumor suppressor in various tumors. However, its role and underlying molecular mechanisms in hepatocellular carcin Show more
Programmed cell death protein 5 (PDCD5) is involved in apoptosis and is regarded as a tumor suppressor in various tumors. However, its role and underlying molecular mechanisms in hepatocellular carcinoma (HCC) remain unclear. PDCD5-overexpressing cell and xenograft tumor models were developed. Cell Counting Kit-8, 5-Ethynyl-2'-deoxyuridine, wound healing, Transwell, flow cytometry, immunohistochemistry, and hematoxylin-eosin staining were employed to explore the effects of PDCD5 on HCC cell behaviors and tumor growth. The enzyme-linked immunosorbent assay and western blot were used to detect pyroptosis-related marker levels. The molecular mechanisms underlying PDCD5's role in HCC were investigated through transcriptome sequencing and coimmunoprecipitation. SRI-011381, a TGF-β signaling activator, was applied to evaluate the impact of PDCD5 in modulating the TGF-β/Smad2/3/Snail pathway. PDCD5 expression was reduced in HCC cells. Overexpression of PDCD5 inhibited HCC cell proliferation, migration, invasion, and xenograft tumor growth. Additionally, PDCD5 overexpression promoted apoptosis and pyroptosis, with corresponding increases in inflammatory factors and Caspase-1, GSDMD, and NLRP3 protein levels. Mechanistically, PDCD5 bound to receptor-regulated Smads (Smad2/3), inhibiting the TGF-β pathway. Treatment with the TGF-β pathway activator SRI-011381 significantly counteracted the inhibitory effects of PDCD5 overexpression on HCC progression. Our findings suggest that PDCD5 impedes the progression of HCC by promoting pyroptosis via regulation of TGF-β/Smad2/3/Snail pathway, which could be a possible therapeutic target for HCC. Show less
no PDF DOI: 10.1016/j.bbadis.2025.167696
SNAI1